Calvin Yeang MD, PhD

Happy Lp(a) Awareness Day! Thanks @TheFHFoundation for raising awareness! #knowlpa

A7: There is hope in the next ~3 years that safe, specific and potent therapies lowering lipoprotein(a) may become available. #KnowLpa

A7: There are exciting therapies currently in clinical trials that prevent the liver from making apo(a) and thereby reducing lipoprotein(a) levels by ~80% at optimal doses. Pelacarsen is currently in phase III and Oliparsiran in phase II clinical trials. #Knowlpa

A6: Clinically, the most important questions are 1) how can we continue to improve risk prediction for those with elevated lipoprotein(a) and 2) does specific lipoprotein(a) lowering reduce cardiovascular disease risk? #KnowLpa

A6: Despite being first described by the geneticist Kare Berg in 1963, there remains so much more to understand about lipoprotein(a). #knowlpa